The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR Therapeutics can replicate the success across its promising pipeline.
Commercial real estate firm CBRE (NYSE:CBRE) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 12.3% year on year to $8.91 billion. Its non-GAAP profit of $0.86 per share was 12.1% above analysts’ consensus estimates.
Boat and marine products retailer MarineMax (NYSE:HZO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 8.3% year on year to $631.5 million. Its non-GAAP profit of $0.23 per share was 19% above analysts’ consensus estimates.
Manufacturing company Dover (NYSE:DOV) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $1.87 billion. Its non-GAAP profit of $2.05 per share was 3.3% above analysts’ consensus estimates.
Aerospace and defense company Textron (NYSE:TXT) announced better-than-expected revenue in Q1 CY2025, with sales up 5.5% year on year to $3.31 billion. Its non-GAAP profit of $1.28 per share was 12.5% above analysts’ consensus estimates.
Higher education company Strategic Education (NASDAQ:STRA) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.6% year on year to $303.6 million. Its non-GAAP profit of $1.30 per share was 34.5% above analysts’ consensus estimates.
Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue to be around $64.85 billion, close to analysts’ estimates. Its non-GAAP profit of $2.22 per share was 4% above analysts’ consensus estimates.
Toy and entertainment company Hasbro (NASDAQ:HAS) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 17.1% year on year to $887.1 million. Its non-GAAP profit of $1.04 per share was 54.7% above analysts’ consensus estimates.
Financial services provider CBIZ (NYSE:CBZ) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 69.5% year on year to $838 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 1.6% below analysts’ estimates. Its non-GAAP profit of $2.29 per share was 8.7% above analysts’ consensus estimates.
A ceasefire between India and Pakistan and a breakthrough U.S.-China trade deal sparked a major rally on Dalal Street; IT, metals, and travel stocks led the surge amid broad-based buying.
Credit reporting company TransUnion (NYSE:TRU) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.3% year on year to $1.1 billion. On the other hand, next quarter’s revenue guidance of $1.09 billion was less impressive, coming in 0.9% below analysts’ estimates. Its non-GAAP profit of $1.05 per share was 7.6% above analysts’ consensus estimates.
Boat and marine manufacturer Brunswick (NYSE:BC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 10.5% year on year to $1.22 billion. On the other hand, next quarter’s revenue guidance of $1.2 billion was less impressive, coming in 3.7% below analysts’ estimates. Its non-GAAP profit of $0.56 per share was significantly above analysts’ consensus estimates.
Architectural products company Apogee (NASDAQ:APOG) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.5% year on year to $345.7 million. The company’s full-year revenue guidance of $1.4 billion at the midpoint came in 2% above analysts’ estimates. Its non-GAAP profit of $0.89 per share was 2.3% above analysts’ consensus estimates.
